June 2021 | Targeted Therapies in Oncology

JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCC

June 26, 2021

Clinical Articles

The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.

Smart Watch Used for Biometric Measuring Demonstrates Positive Response, Overall Satisfaction

June 26, 2021

Clinical Articles

Investigators anticipate that improved versions of the application will evolve over the phases as patient-specific queries are optimized and as cancer-specific pathways are incorporated. A multidisciplinary team will provide a tailored and integrative approach, concluded the investigators.

Nivolumab/Ipilimumab Triplet Improves OS in Advanced NSCLC Compared With Chemotherapy Alone

June 21, 2021

Clinical Articles

A frontline regimen nivolumab, ipilimumab, and 2 cycles of chemotherapy yielded an improvement in overall survival versus chemotherapy alone in patients with advanced non–small cell lung cancer. The benefit was observed regardless of tumor mutational burden status in the tissue or blood.

AMG 757 Elicits Early Response, Safety in Small Cell Lung Cancer

June 18, 2021

First-in-human results of a phase 1 trial (NCT03319940) evaluating AMG 757 in patients with small cell lung cancer revealed early signals of efficacy and a favorable safety profile in findings presented at the European Lung Cancer Virtual Congress 2021.

Adagrasib Reveals Efficacy in KRAS G12CMutated NSCLC

June 17, 2021

Clinical Articles

Updated findings from the early-stage KRYSTAL-1 study showed that treatment with adagrasib resulted in durable responses, broad disease control, and provided extensive predicted coverage throughout the dosing interval in patients with KRAS G12Cmutant advanced non–small cell lung cancer.

Good News: ODAC’s Approvals Are Based on Subjective Decisions

June 16, 2021

Arjun V. Balar, MD, co-physician editor in chief of Targeted Therapies in Oncology, discusses the proceedings of the 3-day Oncologic Drug Advisory Committee meeting on accelerated approvals for PD-1/PD-L1 antibodies in solid tumor indications that failed to show confirmatory benefit.

ODAC Panel Approves 4 of 6 Anti–PD-1/PD-L1 Drugs in Accelerated Approval Program

June 16, 2021

Clinical Articles

An FDA Oncologic Drugs Advisory Committee meeting resulted in continued approval for 4 of 6 indications that were discussed, although all 6 indications did not demonstrate clinical benefit in confirmatory studies. The meeting, held April 27-29, evaluated anti–PD-1/PD-L1 drugs that received accelerated approvals through the FDA’s accelerated approval program, a nearly 30-year-old initiative to expedite the approval process.

Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium Study

June 15, 2021

Results from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.

Anti-TIGIT and ICI Combinations Supported by Early-Phase Research

June 15, 2021

Special Reports

Approaches that pair anti-TIGIT antibodies with other immune checkpoint inhibitors have sparked interest among investigators. Results of early-stage studies evaluating these unique combinations were recently presented at the American Association for Cancer Research Annual Meeting 2021. Later-stage studies are ongoing.